1214254-88-2

Basic information

• Product Name: diethyl {[4-(trans-4-methoxycyclohexylamino)-6-pyrrolidin-1-ylpyrimidin-2-yl]methyl}phosphonate
• Synonyms: diethyl {[4-(trans-4-methoxycyclohexylamino)-6-pyrrolidin-1-ylpyrimidin-2-yl]methyl}phosphonate
• CAS NO: 1214254-88-2
• Molecular Weight: 426.496
• Mol File: 1214254-88-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: diethyl {[4-(trans-4-methoxycyclohexylamino)-6-pyrrolidin-1-ylpyrimidin-2-yl]methyl}phosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl {[4-(trans-4-methoxycyclohexylamino)-6-pyrrolidin-1-ylpyrimidin-2-yl]methyl}phosphonate(1214254-88-2)
• EPA Substance Registry System: diethyl {[4-(trans-4-methoxycyclohexylamino)-6-pyrrolidin-1-ylpyrimidin-2-yl]methyl}phosphonate(1214254-88-2)

Safety Data

• Hazardous Substances Data: 1214254-88-2(Hazardous Substances Data)

Upstream product

• 1214254-80-4 diethyl [(4,6-dichloropyrimidin-2-yl)methyl]phosphonate 
• 760958-17-6 tert-butyl ((1r,4r)-4-methoxycyclohexyl)carbamate 
• 61367-41-7 (1r,4r)-4-methoxycyclohexan-1-amine hydrochloride 
• 19875-05-9 4,6-dichloro-2-(chloromethyl) pyrimidine 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 123-75-1 pyrrolidine 
• 1214254-87-1 diethyl {[4-chloro-6-(trans-4-methoxycyclohexylamino)pyrimidin-2-yl]methyl}phosphonate 

Downstream Products

• 1214254-89-3 2-[(E)-2-(6,7-difluoro-3-methylquinoxalin-2-yl)vinyl]-N-(trans-4-methoxycyclohexyl)-6-pyrrolidin-1-ylpyrimidin-4-amine 

Relevant articles and documents

TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS

The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X1 and X2 is N, and the other of X1 and X2 is CH; A is *-CH═CH—, *-C(Alk)=CH—, *-CH2—CH2— or *-O—CH2— (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.